I want to forward to you today the article published by Confectionerynews.com about the functionality of a chewing gum that contains Cannabidiol (CBD).
The article mentions that inital bioavailability studies show promising results and now the company AXIM Biotech (specialized on research of products containing cannabis) will start clinical trials directed to alleviate symptoms of Irritable Bowel Syndrome (IBS). The bioavailability studies have been conducted with chewing gum containg 30mg of CBD. The current product in the market contains only 10mg of CBD. It is marketed in the USA under the brand Canchew(R). See the link here for the website of the product: Canchew
The gum is made by tabletting process instead of the traditional extrusion process. This is more familiar to pharmaceutical companies and one the best solutions to use chewing gum as delivery system for active ingrendients. The tabletting process has many advanatges (e.g. is done at low temperature, so it does not damage the active ingredient) but also some disadvantages (the chewing profile of the final product is not as “good” as a standard chewing gum, due to the hardness and the dryness of the piece).
Here is the link to the full article from Confectionerynews.com
Chewing Gum Consultant 